Advocacy in Action ESMO 2012: What Is Personalized Medicine
Fortunato Ciardiello (Chair, ESMO Personalized Medicine Working Group) introduces personalized medicine. Vital Options International and the European Society for Medical Oncology (ESMO) presents the 3rd Patient Advocacy in Action, bringing together the influential leaders of the cancer advocacy community to address Personalized Medicine: What it means, its relevance for patients, future research perspectives, collection of tissue specimens, and the role of advocates in shaping public policy discussions.From:vitaloptionsViews:0 0ratingsTime:10:11More inNonprofits Activism

Excerpt from:
Advocacy in Action ESMO 2012: What Is Personalized Medicine - Video

Recommendation and review posted by sam

Advocacy in Action ESMO 2012: Personalized Medicine and Patient Education
Lorenz Jost (Chair, ESMO Patient Working Group) talks about personalized medicine and the importance of educating patients on the topic. Vital Options International and the European Society for Medical Oncology (ESMO) presents the 3rd Patient Advocacy in Action, bringing together the influential leaders of the cancer advocacy community to address Personalized Medicine: What it means, its relevance for patients, future research perspectives, collection of tissue specimens, and the role of advocates in shaping public policy discussions.From:vitaloptionsViews:0 0ratingsTime:03:02More inNonprofits Activism

More:
Advocacy in Action ESMO 2012: Personalized Medicine and Patient Education - Video

Recommendation and review posted by sam

Advocacy in Action ESMO 2012: Key Policy Issues In Personalized Medicine
Francesco De Lorenzo (European Alliance on Personalized Medicine Manifesto) talks about the key policy issues around personalized medicine. Vital Options International and the European Society for Medical Oncology (ESMO) presents the 3rd Patient Advocacy in Action, bringing together the influential leaders of the cancer advocacy community to address Personalized Medicine: What it means, its relevance for patients, future research perspectives, collection of tissue specimens, and the role of advocates in shaping public policy discussions.From:vitaloptionsViews:0 0ratingsTime:06:21More inNonprofits Activism

Read more:
Advocacy in Action ESMO 2012: Key Policy Issues In Personalized Medicine - Video

Recommendation and review posted by sam

Advocacy in Action ESMO 2012: What Is the Future Of Personalized Cancer Medicine In Europe?
Ian Banks (Chair of the ECCO Patient Advisory Committee) talks about the futire of personalized cancer medicine in Europe. Vital Options International and the European Society for Medical Oncology (ESMO) presents the 3rd Patient Advocacy in Action, bringing together the influential leaders of the cancer advocacy community to address Personalized Medicine: What it means, its relevance for patients, future research perspectives, collection of tissue specimens, and the role of advocates in shaping public policy discussions.From:vitaloptionsViews:1 0ratingsTime:05:12More inNonprofits Activism

Read more here:
Advocacy in Action ESMO 2012: What Is the Future Of Personalized Cancer Medicine In Europe? - Video

Recommendation and review posted by sam

Advocacy in Action ESMO 2012: The Challenges Of Genetic Marker Testing Requirements
Kathy Oliver (International Brain Tumor Alliance), Angelo Paolo Dei Tos, MD (Molecular Pathologist, General Hospital in Treviso, Italy) and Fortunato Ciardiello (Chair, ESMO Personalized Medicine Working Group) discuss the challenges of the genetic marker testing requirements for patients. Vital Options International and the European Society for Medical Oncology (ESMO) presents the 3rd Patient Advocacy in Action, bringing together the influential leaders of the cancer advocacy community to address Personalized Medicine: What it means, its relevance for patients, future research perspectives, collection of tissue specimens, and the role of advocates in shaping public policy discussions.From:vitaloptionsViews:0 0ratingsTime:08:58More inNonprofits Activism

Read this article:
Advocacy in Action ESMO 2012: The Challenges Of Genetic Marker Testing Requirements - Video

Recommendation and review posted by sam

Advocacy in Action ESMO 2012: Personalized Medicine and Pathology
Angelo Paolo Dei Tos, MD (Molecular Pathologist, General Hospital in Treviso, Italy), Selma Schimmel Vital Options International) and Stefania Vallone (Women Against Lung Cancer Europe - WALCE) discuss pathology and personalized medicine. Vital Options International and the European Society for Medical Oncology (ESMO) presents the 3rd Patient Advocacy in Action, bringing together the influential leaders of the cancer advocacy community to address Personalized Medicine: What it means, its relevance for patients, future research perspectives, collection of tissue specimens, and the role of advocates in shaping public policy discussions.From:vitaloptionsViews:0 0ratingsTime:16:14More inNonprofits Activism

More:
Advocacy in Action ESMO 2012: Personalized Medicine and Pathology - Video

Recommendation and review posted by sam

Advocacy in Action ESMO 2012: Advocate Perspectives in Tissue Collection and Research
Selma Schimmel (Vital Options International), Kathy Oliver (International Brain Tumor Alliance), Francesco De Lorenzo (European Alliance on Personalized Medicine Manifesto), Jola-Gore Booth (EuropaColon) and Fortunato Ciardiello (Chair, ESMO Personalized Medicine Working Group) discuss tissue collection in cancer research. Vital Options International and the European Society for Medical Oncology (ESMO) presents the 3rd Patient Advocacy in Action, bringing together the influential leaders of the cancer advocacy community to address Personalized Medicine: What it means, its relevance for patients, future research perspectives, collection of tissue specimens, and the role of advocates in shaping public policy discussions.From:vitaloptionsViews:0 0ratingsTime:06:50More inNonprofits Activism

Continue reading here:
Advocacy in Action ESMO 2012: Advocate Perspectives in Tissue Collection and Research - Video

Recommendation and review posted by sam

Advocacy in Action ESMO 2012: Cancer and the Media
Selma Schimmel (Vital Options International), Kathy Redmond (Cancer World Magazine), Jola-Gore Booth (EuropaColon) and Fortunato Ciardiello (Chair, ESMO Personalized Medicine Working Group) discuss the media and cancer reporting. Vital Options International and the European Society for Medical Oncology (ESMO) presents the 3rd Patient Advocacy in Action, bringing together the influential leaders of the cancer advocacy community to address Personalized Medicine: What it means, its relevance for patients, future research perspectives, collection of tissue specimens, and the role of advocates in shaping public policy discussions.From:vitaloptionsViews:0 0ratingsTime:12:15More inNonprofits Activism

The rest is here:
Advocacy in Action ESMO 2012: Cancer and the Media - Video

Recommendation and review posted by sam

Mary Free Bed Holiday Message Montage
During this holiday season, Mary Free Bed Rehabilitation Hospital enjoyed sharing stories that move you. From the Truttman twins who raised money for our Spinal Cord Injury Program to Josh Franklin #39;s contagious smile, their stories remind us all to be grateful for the little things. Thanks to all of you who shared your story, to all of you who liked and commented on those stories, and to all of Mary Free Bed #39;s incredible employees who restore hope and freedom to patients each day. Watch and enjoy this holiday message montage featuring stories from the past couple months. Have a fun and safe holiday!From:MaryFreeBedViews:7 0ratingsTime:01:53More inEducation

The rest is here:
Mary Free Bed Holiday Message Montage - Video

Recommendation and review posted by sam

Glendale, AZ Personal Injury Auto Accident Attorney - David R. Farney, PLC
Highly Experienced http://www.azinjuryatty.com David R. Farney, PLC is a comprehensive personal injury law firm in Glendale, AZ representing victims of all types of personal injuries. Whether your injury occurred in an automobile or a truck accident, as the result of using a defective product or involved a serious brain or spinal cord injury, we are equipped to handle your case. Following your free initial consultation, we conduct a thorough investigation into the circumstances of your injury. Tapping into a useful network of resources that includes accident reconstruction specialists and other experts, we investigate thoroughly. As a top auto accidents attorney in Glendale, AZ, our firm knows how to explore all possibilities mdash; from poor road conditions, to reckless drivers, to tire manufacturer defects mdash; to determine responsibility.From:LawyersdotcomViews:0 0ratingsTime:01:00More inEducation

The rest is here:
Glendale, AZ Personal Injury

Recommendation and review posted by sam

Researcher Profile: Arthur Brown
Schulich School of Medicine Dentistry Associate Professor and Robarts Research Institute scientist, Arthur Brown, discusses his passion for spinal cord injury research, what his lab is currently working on and how he hopes to see his research impact spinal cord injury in the future.From:WesternUniversityViews:10 1ratingsTime:02:39More inEducation

Read more here:
Researcher Profile: Arthur Brown - Video

Recommendation and review posted by sam

SEPVA_PSA1.mov
"Twila gave, you can too" The Southeastern Chapter of the Paralyzed Veterans of America requested support to help US Veterans with spinal cord injury and/or disease for a better quality of life.From:Jennifer WViews:2 0ratingsTime:01:01More inPeople Blogs

Visit link:
SEPVA_PSA1.mov - Video

Recommendation and review posted by sam

PhD training programme
Stem cells regenerative medicine is an exciting and fast moving field that brings together experts in biology, medicine, chemistry, engineering and other areas to find solutions to some of the most challenging scientific and medical problems we face today. The MRC Centre for Regenerative Medicine at the University of Edinburgh offers an integrated and structured PhD training programme in stem cells and regenerative medicine, incorporating taught and research elements to provide high-level training in theoretical and practical stem cell research. More info: http://www.crm.ed.ac.ukFrom:CRMedinburghViews:5 0ratingsTime:01:56More inPeople Blogs

Follow this link:
PhD training programme - Video

Recommendation and review posted by sam

A gene inserted into ordinary heart cells transformed them into rare "pacemaker" cells that regulate cardiac rhythm, according to experiments carried out on lab rodents.

The research is a step toward the goal of a biological fix for irregular heartbeat, which at present is tackled by drugs or electronic pacemakers, its investigators said.

The heart has 10 billion cells but fewer than 10,000 are pacemaker cells, which generate electrical activity that spreads to other cardiac cells, making the organ contract rhythmically and pump blood.

The work, reported in the journal Nature Biotechnology, uses a virus to deliver a human gene called Tbx18, whose normal role is to coax immature cells into becoming pacemaker cells.

Ordinary cells "infected" by the harmless Trojan horse were reprogrammed by Tbx 18 and became these important specialised cells.

"The new cells generated electrical impulses spontaneously and were indistinguishable from native pacemaker cells," said Hee Cheol Cho at the Cedars-Sinai Heart Institute in Los Angeles, California.

The promising technique builds on decade-long research into biological pacemakers. So it has so far been tested on guinea pigs and rats.

Read more from the original source:
Gene turns cells into 'pacemaker'

Recommendation and review posted by Bethany Smith

A gene inserted into ordinary heart cells transformed them into rare "pacemaker" cells that regulate cardiac rhythm, according to experiments carried out on lab rodents.

The research is a step toward the goal of a biological fix for irregular heartbeat, which at present is tackled by drugs or electronic pacemakers, its investigators said.

The heart has 10 billion cells but fewer than 10,000 of them are pacemaker cells, which generate electrical activity that spreads to other cardiac cells, making the organ contract rhythmically and pump blood.

The work, reported in the journal Nature Biotechology on Sunday, uses a virus to deliver a human gene called Tbx18, whose normal role is to coax immature cells into becoming pacemaker cells.

Ordinary cells "infected" by the harmless Trojan horse were reprogrammed by Tbx 18 and became these important specialised cells.

"The new cells generated electrical impulses spontaneously and were indistinguishable from native pacemaker cells," said Hee Cheol Cho at the Cedars-Sinai Heart Institute in Los Angeles, California.

The promising technique builds on decade-long research into biological pacemakers. So it has so far been tested on guinea pigs and rats.

"We expect this to work in humans. It would be two to three years from now until the first clinical trial, the first target patients being the ones with (pacemaker) device infection," Cho said in an email to AFP.

Here is the original post:
Gene turns heart cells into pacemaker: lab study

Recommendation and review posted by Bethany Smith

A mutation in a certain gene linked to an increased risk of breast and ovarian cancer could help with prevention measures, research has found.

A team of researchers led by the Institute of Cancer Research (ICR) found that mutations in a gene called PPM1D is linked to an increased risk of the two cancers.

Women with PPM1D mutations have a 20% chance of developing breast or ovarian cancer - double the breast cancer risk and more than 10 times the ovarian cancer risk of women in the general population. But the discovery could help with genetic testing and prevention in particular for ovarian cancer, which is often diagnosed at an advanced stage.

The study, published in the journal Nature this week, said that PPM1D seems to be working in a completely different way to other genes known to increase the risk of breast and ovarian cancer, such as BRCA1 and BRCA2.

Study leader Professor Nazneen Rahman, head of genetics at the ICR and head of the cancer genetics clinical unit at The Royal Marsden NHS Foundation Trust, said: "This is one of our most interesting and exciting discoveries.

"At every stage the results were different from the accepted theories. We don't yet know exactly how PPM1D mutations are linked to breast and ovarian cancer, but this finding is stimulating radical new thoughts about the way genes and cancer can be related.

"The results could also be useful in the clinic, particularly for ovarian cancer which is often diagnosed at an advanced stage. If a woman knew she carried a PPM1D mutation and had a one in five chance of developing ovarian cancer, she might consider keyhole surgery to remove her ovaries after completing her family."

The team analysed 507 genes involved in DNA repair in 1,150 women with breast or ovarian cancer, identifying PPM1D gene mutations in five women. They then sequenced the PPM1D gene in 7,781 women with breast or ovarian cancer and 5,861 people from the general population. There were 25 faults in the PPM1D gene in women with cancer and only one in the general population, a highly statistically significant difference.

Professor Alan Ashworth, ICR chief executive and one of the study researchers, said: "This discovery really does turn conventional wisdom about the way genetic mutations can lead to cancer on its head. "As we unravel this puzzle, we are likely to gain valuable insights about how cancer develops, and new tools for assessing people's risk of the disease and targeting preventive treatment."

The study was funded by the ICR, the Wellcome Trust, Cancer Research UK and Breakthrough Breast Cancer.

Continue reading here:
Mutation in gene could fight cancer

Recommendation and review posted by Bethany Smith

Genetic Engineering Infomercial.m4v
From:Shaista DhanesarViews:0 0ratingsTime:12:23More inPeople Blogs

View original post here:
Genetic Engineering Infomercial.m4v - Video

Recommendation and review posted by Bethany Smith

The Scoop on Genetic Engineering
A bacteria (E-Coli) and or a virus is used to invade the cell of a species or organism by inserting (forcing) a gene from another incompatible species or organism with a desired trait. Genetically Modified Organisms are linked to disorders such as pre-mature aging, allergies, inflammatory bowel disease, infertility, autism, cancer and more. The natural way of creating a hybrid plant is by crossing and re-crossing plants of compatible species for desired traits. For more information and videos http://www.babyboomerfitnessusa.comFrom:Paul GiomiViews:1 0ratingsTime:02:29More inNonprofits Activism

Originally posted here:
The Scoop on Genetic Engineering - Video

Recommendation and review posted by Bethany Smith

SHERWOOD, Ore., Dec. 17, 2012 /PRNewswire/ -- Entia Biosciences (ERGO), a food science biotechnology company and emerging leader in the fields of Nutrigenomics and Targeted Nutrition, has received a Patent Notice of Allowance from the Canadian Intellectual Property Office covering the use of Ergothioneine and its genetic transporter (SLC22A4) in the treatment of a wide variety of diseases, including those affecting the immune and central nervous systems. Ergothioneine is a powerful amino acid and master antioxidant that is acquired exclusively from the diet and carried by this unique and specific transporter to cells throughout the body that are fighting damage and death from oxidative stress and toxic free radical reactions. Research conducted by Entia since 2011 has confirmed significant transporter activity in diabetes, arthritis, and several other serious non-communicable chronic conditions, suggesting an important physiologic role for Ergothioneine in diseases affecting millions of people world-wide.

"We are very pleased that our intellectual property estate on Ergothioneine is advancing nicely alongside the scientific, clinical and other business developments at Entia," said Marvin S. Hausman MD, Chairman and Chief Executive Officer. "The issuance of this important foundational patent significantly enhances the commercialization strategy for our ErgoD2 line of proprietary medical foods, functional ingredients, and other nutritional supplementation solutions in 2013 and for the potential development of a commercial diagnostic test that could one day identify specific dietary deficiencies."

Found in naturally high concentrations almost exclusively in mushrooms and other fungi, Ergothioneine is transferred directly from these sources into the soil, where it is taken up by plants and grazing mammals. For thousands of years, our hunter/gatherer genetics have relied on this process to maintain adequate levels of Ergothioneine to prevent or delay the onset and progression of disease. Entia theorizes introduction of modern agricultural practices in the past century, such as the heavy use of chemical fertilizers, insecticides, and over tilling of the soil, has been gradually eradicating mushrooms from our farmland and depleting Ergothioneine from the food supply. During this same period, our dietary habits have been changing, which Entia believes is further accelerating deficiency in the general population and may explain the dramatic increases we are now seeing in diabetes, arthritis, neurodegenerative, and other debilitating diseases. This deficiency theory is supported by human blood testing conducted in the late 1920s1 that showed "normal" Ergo levels nearly double those found by Pennsylvania State University in 20102.

Discovered in 2005 by Dr. Dirk Grundemann at the University of Cologne (Germany), SLC22A4 is a sodium-ion dependent transporter that efficiently and specifically carries Ergothioneine across the cell membrane to erythrocytes (red blood cells), progenitor stem cells, and monocytes (white blood cells) (Grundemann, 2005). Variations in SLC22A4 have been associated with susceptibility to inflammatory disorders, such as rheumatoid arthritis and Crohn's disease, and expression has been documented in a variety of human tissues. Entia licensed the exclusive world-wide diagnostic and therapeutic rights to the discovery from the University of Cologne in 2010 and Dr. Grundemann currently serves on Entia's Scientific Advisory Board.

Dr. Solomon Snyder of Johns Hopkins University School of Medicine has suggested that Ergothioneine is as potent as glutathione and because of its dietary origin and the toxicity associated with its depletion, it may represent a new vitamin whose physiologic roles include antioxidant cytoprotection. Dr. Snyder further believes that the high density of Ergothioneine within mitochondria implies a unique role in protecting mitochondrial DNA from damage induced by free radicals and reactive oxygen species (Snyder, 2009). Mitochondria are cytoplasmic organelles responsible for life and death. Evidence from animal and clinical studies suggest that mitochondria play a critical role in aging, cancer, diabetes and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease (Simon, 2004; Lin, 2006; Reddy, P.H., 2009). Further supportive evidence of the potential protective role of Ergothioneine was recently shown by the presence of elevated levels in the red blood cells of pregnant women with the condition preeclampsia. There is currently no known cause for this condition, which affects nearly 10% of pregnancies reaching 20 weeks. The symptoms of preeclampsia include high blood pressure, protein in urine, and fluid retention and left untreated the condition can cause a range of problems such as growth restriction in babies and even fetal and maternal mortality. Ergothioneine is known as an antioxidant and antioxidants have been proposed to be helpful in reducing the risk of preeclampsia. It is therefore very interesting that we have found it to be in excess for women with the condition (Turner, E., 2009)."

About Entia Biosciences, Inc.

Entia is an authority on the clinical effects of oxidative stress and free radical reactions and is bringing this expertise to the fields of food science biotechnology and nutrigenomics. The Company identifies, scientifically validates, patents, and commercializes solutions that address multi-billion dollar markets for health, beauty and agriculture.

For more information, please visit our web sites at http://www.entiabio.com or contact:

Devin Andres Vice President Entia Biosciences, Inc. 13565 SW Tualatin-Sherwood Rd Sherwood, OR, 97140 Phone: 503-334-3575 Email: info@entiabio.com

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2011 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Read more here:
Entia Receives Canadian Patent Notice of Allowance for Use of Ergothioneine and its Genetic Transporter

Recommendation and review posted by Bethany Smith

NEW YORK, Dec. 17, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

North America In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture http://www.reportlinker.com/p0763031/North-America-In-Vitro-Diagnostics-Market-Outlook-to-2018--Clinical-Chemistry-Genetic-Testing-Haematology-Histology-and-Cytology-Immuno-Chemistry-Infectious-Immunology-and-Microbiology-Culture.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

North America In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

GlobalData's new report, "North America In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture" provides key market data on the North America In Vitro Diagnostics market Canada and United States. The report provides value (USD million) data for all the market categories Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

- Countries covered include Canada and United States. - Market size and company share data for In Vitro Diagnostics market categories Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. - Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2004 to 2011, forecast forward for 7 years to 2018. - 2011 company shares and distribution shares data for each of the market categories and countries. - Global corporate-level profiles of key companies operating within the North America In Vitro Diagnostics market.. - Key players covered include Siemens Healthcare, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., Alere Inc. and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth. - Develop market-entry and market expansion strategies. - Design competition strategies by identifying who-stands-where in the North America In Vitro Diagnostics competitive landscape. - Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future. - What are the key distribution channels and what's the most preferred mode of product distribution Identify, understand and capitalize.

The rest is here:
North America In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology ...

Recommendation and review posted by Bethany Smith

NORTH KINGSTOWN, R.I., Dec. 17, 2012 /PRNewswire/ --Dominion Diagnostics has entered into an exclusive agreement with LifeGen, Inc. for the licensing rights to patented genetic testing. Currently the two companies are involved in a research study aimed at validating the testing against the Addiction Severity Index (ASI) designed and marketed by Inflexxion, Inc. The research results are on track to be released in the first quarter of 2013, and are expected to show that LifeGen's test is valuable in determining a patient's Genetic Addiction Risk Score (GARS), or relative predisposition in manifesting addictive behaviors. Approximately 400 patient subjects selected from addiction treatment facilities across the country are involved in the GARS analysis.

The GARS analysis is set to investigate a panel of genes primarily involved in brain reward circuitry. For 30% of the human population (approximately 100 million people), genetics are a large factor in dopamine-driven addiction. This subset of the population carries the DRD2 Type A1 receptor gene which induces low dopamine brain function that results in the propensity for addictive cravings. The GARS test involves a number of reward genes and related polymorphisms which have significant impact on substance use disorders.

LifeGen's Kenneth Blum, PhD is the primary investigator on the companies' current research. Blum is credited with the first known association of the dopamine D2 receptor (DRD2) gene with alcoholism and other addictive behaviors including drug addiction, smoking, overeating, gambling, and sex (Blum & Noble, JAMA, 1990).

"I am confident that the results from our mutual research will provide clinical evidence associating the GARS test with the Addiction Severity Index (ASI)," Dr. Blum said. "The GARS analysis will ultimately be an important front line 'window' into the brain of millions enabling the clinician with genetic information and taking out the guess work to identify those at risk for all addictive behaviors."

In the last decade, genetic variants in the Cytochrome P450 (CYP450) system have been identified and pharmacogenetic testing has been developed that can distinguish differences in a patient's ability tometabolize drugs.Although most insurers do not currently cover the cost of testing, Dominion has determined that there isa critical need to classify patients at genetic risk for drug seeking behavior or addiction prior to treatment. The risk severity associated with a predisposition to addiction, due to polymorphisms in the DRD2 gene rather than genes in the CYP450 system may have greater clinical relevance to today's epidemic level of drug abuse and misuse.

Dominion Diagnostics and LifeGen, Inc. are confident that their GARS analysis results will provide valuable information in a multitude of medical specialties, including but not limited to addiction treatment, pain management, primary care, family medicine, and adolescent treatment.

About Dominion Diagnostics

Dominion Diagnostics is a leading national monitoring company that offers comprehensive medication and substance use monitoring services and a full suite of clinical support solutions. Since 1997, Dominion Diagnostics has provided services to thousands of clients representing a diversity of medical specialties across the United States, including addiction medicine, behavioral health, pain medicine, primary care, psychiatry, and hospital systems. Dominion Diagnostics is supported by a world-class team that shares a commitment to clinical excellence, compliance, and integrity. For more information, please visit http://www.dominiondiagnostics.com.

About LifeGen, Inc.

LifeGen, Inc. (LG) is a vertically integrated nutrigenomic technology company with offices in the suburbs of Philadelphia Pennsylvania, Austin Texas, and San Diego California. LG is the first "nutrition gene therapy" company utilizing "polygenic targeting" as a platform technology for personalized medicine. LG is the only known company holding patents from the USA and Europe that couples DNA testing with a customized nutrigenomic solution. LG is the pioneer, leader, and gold standard of DNA-directed precision nutrition, especially in the realm of neuroendocrine science. With over 100 years of team research experience conducted on the genetic and nutritional causes of many common healthcare concerns, LG provides non-prescription nutrigenomic health solutions to people based on DNA targets that optimize gene expression. For more information, please visit http://www.rewarddeficiencysyndrome.com.

Read more here:
Exclusive Agreement for Genetic Testing and Research Announced Between Dominion Diagnostics and LifeGen, Inc.

Recommendation and review posted by Bethany Smith

Effects of Steroids on the Body
Genetics Project for Ms. Amanda WagnerFrom:Sam DiCaroViews:0 0ratingsTime:02:44More inScience Technology

More here:
Effects of Steroids on the Body - Video

Recommendation and review posted by Bethany Smith

Mission Control - Genetics
Mission Control live at Cloud 9 12/15/12!!!!! http://www.facebook.comFrom:RaisingtheGutterViews:3 0ratingsTime:04:00More inMusic

Read more:
Mission Control - Genetics - Video

Recommendation and review posted by Bethany Smith

IUFO Congress 2010 Melinda Leslie Niara Isley - The Reality of Government Sponsored Covert-ops 8/8
Melinda Leslie Niara Isley Presents The Reality of Government Sponsored Covert - Ops Abduction Experiences Melinda Leslie will discuss how the covert-ops #39; reverse-engineering of extraterrestrial abductees is redefining both the UFO cover-up and abduction paradigms by showing that the management of ET related information and technology includes the monitoring and re-abduction of alien abductees. She explains that just as covert-ops personnel gathers and reverse-engineers ET craft, they also gather and reverse-engineer abductees - and for the same reason - furthering development of secret technology programs and control of ET information. She #39;ll explain that military person:X-XML: nel surveillance, re-abduct and interrogate abductees to gather information on the ET #39;s motives, ET genetics, abductee psi (paranormal) abilities and ET technology. Melinda will share startling new developments, the evidence, and experiences from her research and how this covert-ops #39; involvement may be the best evidence for the reality and importance of UFO abduction. Additionally, Melinda #39;s presentation demonstrates why there can #39;t be an official disclosure without it addressing the abduction phenomenon. Following her will be Niara, a powerful first-hand example of many of the latest developments. FAIR USE NOTICE:Any copyrighted material is for the sole purpose of educatoin and NO profit in any way is being obtainedFrom:speedsterDyViews:2 0ratingsTime:15:11More inScience Technology

The rest is here:
IUFO Congress 2010 Melinda Leslie

Recommendation and review posted by Bethany Smith

Superhero Genetics!
Allan MaxFrom:aht0123Views:1 0ratingsTime:06:26More inPeople Blogs

See more here:
Superhero Genetics! - Video

Recommendation and review posted by Bethany Smith